Health Care ETFs Have Lost In The Last Month – These Top Pharma Stocks Are The Reason
The Health Care Select Sector SPDR Fund (NYSE:XLV), heavily tilted towards mega-caps, lost around 5.25% over the last month, with substantial companies…
Analyst Downgrades Gossamer Bio As Merck’s Sotatercept Might Overshadow Seralutinib’s Success
Raymond James has downgraded Gossamer Bio Inc (NASDAQ:GOSS) to Market Perform from Outperform following the publication of sotatercept’s Phase 3 data in NEJM. …
US Justice Department Sues To Block JetBlue’s $3.8B Spirit Airlines Deal
The Justice Department has reportedly sued to block JetBlue Airways Corporation (NASDAQ:JBLU) and Spirit Airlines Incorporated (NYSE:SAVE), the Biden administration’s latest attempt…
FDA’s Regulatory Delay is The Reason For Novavax, Lucira Health’s Failure: WSJ Report
Failures of Covid vaccine maker Novavax Inc (NASDAQ: NVAX) and diagnostic start-up Lucira Health Inc (NASDAQ: LHDX) show that companies often succeed or fail, owing to the whims of the government.&nb
Why BioMarin Shares Are Plunging Today?
Biomarin Pharmaceutical Inc (NASDAQ: BMRN) shares are falling in reaction to positive data from BridgeBio Pharma Inc's (NASDAQ: BBIO) dwarfism drug, heating the competition.
Medtronic Says PulseSelect Ablation System Demonstrates ‘Impressive Results’
Medtronic plc (NYSE:MDT) announced that its PulseSelect Pulsed Field Ablation (PFA) System exceeded its safety performance goal, with an adverse…
Clene’s Lead Amyotrophic Lateral Sclerosis Shows Improved Function, Slowed Disease Progression
Clene Inc (NASDAQ:CLNN) announced new results showing preserved ALS patient functional score (ALSFRS-R) and delayed time to clinical worsening from the…
Investors Cheer Armata Pharma’s Encouraging Data From Lung Infection Candidate
Armata Pharmaceuticals Inc (NASDAQ:ARMP) announced positive topline results from the completed Phase 1b/2a SWARM-P.a. trial evaluating AP-PA02 for chronic pulmonary Pseudomonas aeruginosa infections in…
BioCardia Outlines Detailed Cell Therapy Data From Heart Failure Study
BioCardia Inc (NASDAQ:BCDA) presented detailed echocardiography data from the roll-in cohort of the Phase 3 CardiAMP Cell Therapy Heart Failure Trial.…
BridgeBio’s Dwarfism Candidate Shows Favorable Height Increase, Safety Profile
BridgeBio Pharma Inc (NASDAQ: BBIO) announced results from PROPEL2 Phase 2 trial of infigratinib in children with achondroplasia, a genetic condition affecting a protein in the body called the fibroblast growth factor receptor.